



FDC Limited

MANUFACTURERS & EXPORTERS OF FOODS, DRUGS & CHEMICALS

Date:- August 08, 2024

To,

BSE Limited

Phiroze Jeejeebhoy Towers,

Dalal Street,

Mumbai- 400 001.

BSE Script Code: 531599

National Stock Exchange of India Ltd.

Exchange Plaza, Plot no. C/1, G Block,

Bandra-Kurla Complex, Bandra (E),

Mumbai - 400 051.

NSE Symbol: FDC

Sub: Press Release on Q1 - FY 2024-25 Results.

Dear Sir/Ma'am,

Please find attached herewith the Press Release issued in relation to the Unaudited Standalone and Consolidated Financial Results of the Company for the Quarter ended June 30, 2024.

Kindly take the same on record.

Thanking you,

Yours truly

For FDC Limited

Varsharani Katre

Company Secretary & Compliance Officer

M No.: FCS-8948




FDC Limited

MANUFACTURERS & EXPORTERS OF FOODS, DRUGS & CHEMICALS

FDC Limited reports Q1FY25 results

Mumbai, 7th Aug 2024: FDC Limited (NSE: FDC, BSE: 531599, ISIN: INE258B01022) reported financials for the first quarter ended 30th June 2024.



Consolidated Q1FY25 FDC reported

Rs. in crores	Q1FY25	Q1FY24	YoY Growth %
Operating Revenue	638	536	19.0%
EBITDA	147	122	20.2%
EBITDA %	23.0%	22.7%	
PBT	163	141	15.6%
PAT	119	110	13.5%
EPS (Rs.)	7.31	6.62	15.7%

Commenting on the results;

We are pleased to announce a healthy revenue and profitability growth during the first quarter of the current financial year backed by robust performance in domestic formulation business growing by 23.6% YoY. With no regulatory price revision permitted on the scheduled products, the company has been able to sustain the overall revenue and profitability growth with optimization of the operating expenses. Export formulation business although reported de growth by 6.8% YoY due to lower sales in certain regulated markets. API business continues to show steady state growth of 6.2% YoY during the first quarter.

With more focus on costs optimization, efficiency improvement and other income from treasury surplus, the Company has been able to report healthy growth in profit before tax at 15.6% YoY.



CORPORATE OFFICE : 142-48, S. V. Road, Jogeshwari (W), Mumbai - 400 102. INDIA
Tel.: +91-22-6291 7900 / 950 / 2678 0652 / 2653 / 2656 • Fax : +91-22-2677 3462
E-mail : fdc@fdcindia.com • Website : www.fdcindia.com

REGISTERED OFFICE : B-8, M.I.D.C. Industrial Area, Waluj - 431 136, Dist. Aurangabad. INDIA
Tel.: 0240-255 4407 / 255 4299 / 255 4967 • Fax : 0240-255 4299
E-mail : waluj@fdcindia.com • CIN : L24239MH1940PLC003176

Business-wise Sales Performance

₹ Cr	Q1FY25	YoY Grw %
Net Sales	638	19.0%
India Formulations	549	23.6%
US Formulations	20	-43.6%
Emerging Markets	43	34.5%
API Sales	25	6.2%

India Market:

The sale of branded formulations in India for Q1FY25 was Rs. 549 crores, with a growth of 23.6% on YoY and 54.4% on QoQ. Overall sales in the Indian market accounted for 86% of total consolidated sales for the quarter.

As per secondary sales data by IQVIA for the quarter ended June 30, 2024, the Company delivered YoY growth of 8.6% compared to the Indian Pharmaceutical Market (IPM) growth of 7.6% YoY. Electral has moved up to 18th in IPM in MAT Jun'24 as compared to 26th in the same period last year. Electral is the 2nd fastest growing product among the Top 2 products of IPM in MAT Jun-24.

Export Formulations Market:

Formulation Sales in the Export market were Rs. 63 crores in Q1FY25, down by 6.8% over YoY and lower by 16.3% over QoQ and accounted for 10% of total consolidated sales.

API Business:

API Sales were Rs. 25 crores in Q1FY25, up by 6.2% over YoY and lower by 7.4% over QoQ and accounted for 4% of total consolidated sales.



A handwritten signature in blue ink, appearing to be "S. S. S.", written over a light blue circular stamp.

ABOUT FDC LTD

FDC was established in the year 1936 as a partnership firm. This firm was incorporated as a Company in 1940, with the vision of building a world-class company while contributing to making the nation self-reliant in healthcare. To cite a few, FDC carries forward the flaming spirit of its first dream, achieving accreditations from the US-FDA, UK-MHRA, MCC-RSA, and the UAE. FDC is a forerunner in the manufacturing and marketing of Oral Rehydration Salts (ORS), anti-infectives and ophthalmic. FDC has also set up globally approved, multi-location manufacturing facilities for Active Pharmaceuticals Ingredients (APIs) as well as Finished Dosage Forms. These facilities are located at Roha, Waluj and Sinnar in Maharashtra, Verna in Goa and Baddi in Himachal Pradesh. FDC markets more than 300 products in India and exports many of these to over 50 countries. FDC strives to explore, innovate and integrate solutions with modern technology, empowering talent and expanding healthcare horizons for a better quality of life for millions globally.

Disclaimer

Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward-looking statements". These forward-looking statements involve several risks and uncertainties including the impact of Covid-19 and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include, but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, our ability to obtain regulatory approvals, technological changes, fluctuation in earnings, foreign exchange rates, our ability to manage international operations and exports, our exposure to market risks as well as other risks.



A handwritten signature in blue ink, appearing to be "S. K. S. S.", written in a cursive style.